1 week ago
Aurobindo Pharma’s US Unit Reports Four FDA Observations
The US FDA checked one of Aurobindo Pharma’s American units.
The check happened from 17 to 21 August 2026.
Inspectors listed four observations at the Lannett Company facility.
Aurobindo Pharma said these observations were about procedures.
The company said it would send its response on time.
Inspectors also checked AuroPeptides in Telangana, India.
That inspection found one issue involving facility and equipment maintenance.
Aurobindo Pharma said corrective action had already started for that issue.
The US FDA inspected Aurobindo Pharma’s subsidiary Lannett Company LLC from 17 to 21 August 2026.
The inspection at Lannett’s Seymour, Indiana, facility concluded with four observations.
Aurobindo Pharma described the observations as procedural and said it will respond within the required timeline.
A separate inspection at AuroPeptides Ltd in Telangana found one observation concerning facility and equipment maintenance.
Aurobindo Pharma shares rose more than 1% to an intraday high of ₹1,637.75 on 24 August.
- Who
- The United States Food and Drug Administration inspected facilities operated by Lannett Company LLC and AuroPeptides Ltd, subsidiaries of Aurobindo Pharma.
- What
- The Lannett inspection resulted in four observations, while the AuroPeptides inspection resulted in one observation.
- Where
- Lannett Company LLC was inspected in Seymour, Indiana, United States; AuroPeptides Ltd was inspected in Indrakaran Village, Kandi Mandal, Sangareddy District, Telangana.
- When
- Both inspections took place from 17 to 21 August 2026; Aurobindo Pharma disclosed the Lannett findings on 24 August and the AuroPeptides findings on 21 August.
- Why
- The inspections were routine regulatory checks by the US FDA.
Key facts
- US subsidiary
- Lannett Company LLC, Aurobindo Pharma’s wholly owned step-down subsidiary
- Lannett inspection result
- Four observations
- Lannett inspection location
- Seymour, Indiana, United States
- AuroPeptides inspection result
- One observation
- AuroPeptides issue
- Facility and equipment maintenance; the company said it did not concern data integrity or related GMP compliance
- Share-price move
- The stock reached an intraday high of ₹1,637.75 after rising more than 1% on 24 August
- Recent stock performance
- The shares were up 36% year-to-date and 54% over the previous year, according to the article
Quotes
Aurobindo Pharma
The pharmaceutical company, commenting on the AuroPeptides inspection
“Corrective action was already initiated during the course of the inspection, and our formal response will be submitted within the stipulated timeline.”
livemint.com
Sources
Related news
US FDA Inspection Finds Three Observations at Apitoria Plant
Aurobindo's Eugia Pharma Telangana Unit Gets USFDA Warning Letter
USFDA Warns Dabur India Over Manufacturing Lapses at Silvassa Plant
Dr Reddy's receives four USFDA observations for Hyderabad plant
USFDA Warns Reliance Life Sciences Over Navi Mumbai Drug Lapses
US FDA hails Andhra Pradesh pharma, urges stricter quality checks
